>1400 registered participants from over 40 countries , over 300 questions answered - I love our annual patient conference ❤️❤️

❤️

ERJ Podcast January 2026: Cannabis and the lung As part of the January issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews editorial board member Janice Leung about the clini

ERJ Podcast: @profjdchalmers.bsky.social interviews editorial board member Janice Leung about the clinical, physiological, imaging and molecular responses to cannabis smoking seen in the CANUCK study https://ow.ly/uSYj50Y5jli

Thank you!
Come visit !

ERJ Podcast December 2025: Year in review As part of the December issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers and Deputy Chief Editor Don Sin for their end-of-year roundup

As part of the December issue, the European Respiratory Journal presents the latest in its series of podcasts. @profjdchalmers.bsky.social and Don Sin for their end-of-year roundup of their highlights from the ERJ in 2025. https://on.soundcloud.com/SK1FF0Vk7bDdRb4K4M

The Blue Journal thanks Hayoung Choi, MD, PhD, ATSF, for his contribution to the December issue

Upper-Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study
@profjdchalmers.bsky.social

www.atsjournals.org/doi/full/10....

Thanks to @profjdchalmers.bsky.social, the landmark research could help 1.3 million people living in the UK with the lung condition. But too many people are waiting years for a diagnosis – and without one, they miss the chance to get access to life-changing treatment.

Professor James Chalmers to join the Radcliffe Department of Medicine We are delighted to announce that Professor James Chalmers has been recruited to the statutory Rhodes Professorship of Experimental Therapeutics and Clinical Pharmacology at the University of Oxford. ...

We are delighted to welcome @profjdchalmers.bsky.social to @rdm.ox.ac.uk as the Rhodes Professor of Experimental Therapeutics and Clinical Pharmacology. James conducts clinical trials and translational research to understand airway disease and develop new therapies. www.rdm.ox.ac.uk/news/profess...

Thank you!
Thrilled to take up this new role and to expand our work to improve the lives of people with lung and inflammatory conditions
Science changes lives

Our first speaker at the #CPGonLungHealth is @profjdchalmers.bsky.social . He talks about the world leading work that has been led from his team in Dundee. It’s a condition that doesn’t get the focus it needs and it is incredible what has been achieved in the last 14 years @emmaharpermsp.bsky.social

Broad Immunomodulatory Effects of the Dipeptidyl Peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial

A novel treatment for bronchiectasis

@profjdchalmers.bsky.social

www.atsjournals.org/doi/full/10....

Thanks to Emma Johnson, MBBS, MSc, PhD, for contributing to the May issue

Broad Immunomodulatory Effects of the DPP1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW Trial

@profjdchalmers.bsky.social

www.atsjournals.org/doi/10.1164/...

Such an honor and a privilege to share the stage with Rene Wyndham, Susanne Vijverberg, Saglani Sejal, @profjdchalmers.bsky.social, Rory Morty, Sara Cuevas Ocaña and @danielchengyuwu.bsky.social for the early-career delegates session of the 2025 edition of the ERS Lung Science Conference #LSC2025.

European #Bronchiectasis Patient Conference suggestion: bring the checklist to your doctor!!! Am I getting ALL of these recommendations??

#Bronchiectasis patient conference was excellent today - even kept me in on a rare sunny day in Scotland - but I got out for a walk afterwards

@profjdchalmers.bsky.social

🔥 🔥 🔥 Hot of the press: Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis

buff.ly/CGXv34s

European #Bronchiectasis Pt Conf Sat, March 15th‼️
Amazing experts participating:
✅ Dr. James Chalmers (aka Dr. Bronchiectasis!) from Scotland
✅ Dr. Michal Shteinberg from Israel
✅ Dr. Pamela McShane from the US
…and other international experts!
tinyurl.com/2r5nh6rh

🌟Day 2 at #EBROW25: Breaking New Ground!🌟

Exciting updates on new treatments for #bronchiectasis and #NTM infections from Prof. @profjdchalmers.bsky.social from @dundee.ac.uk & Prof. Charles Daley from @nationaljewish.org

💬 Insightful, interactive, and inspiring!

We have so much to learn about the heterogenous disease that is Bronchiectasis! Dr. Thi shared some of the excellent work that is being done around the world, led by @profjdchalmers.bsky.social and colleagues, including therapies to reduce neutrophilic inflammation.

Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study The clinical characteristics of patients with bronchiectasis in China show differences compared with cohorts in Europe and India. Bronchiectasis is more severe with a higher burden of exacerbations in...

📓We have an #OpenAccess Article reporting on the Baseline characteristics of patients in the Chinese #Bronchiectasis Registry

“The management of patients with bronchiectasis in China urgently needs standardisation and improvement”

www.thelancet.com/journals/lan...

@profjdchalmers.bsky.social

Really enjoyed #RTI2025 & chatting all things 🫁 infection. Many thanks to the organisers for asking me to speak.

Also super proud of Elen Vink for winning the poster prize for her work on the CHARISMA Study. 🏆🥳🙌

@lenagroup4resp.bsky.social
@profjdchalmers.bsky.social
@dbogaert.bsky.social

🆕️✨️Large cohort
Administration of Macrolide maintenance therapy in patients with bronchiectasis was associated with a significant reduction in the risk of MACE, without any evidence suggesting an increased risk of severe arrhythmia-related AEs #idsky
publications.ersnet.org/content/erj/...

Upcoming journal club "Extensive Acute and Sustained Changes to Neutrophil Proteomes Post-SARS-CoV-2 Infection" on 14 Jan @ 11amET/2pmPT. Register thoracic.zoom.us/meeting/regi... site.thoracic.org/events/exten... @ats-aii.bsky.social @ats-assemblies.bsky.social @profjdchalmers.bsky.social

Sotatercept approved to treat adult patients with pulmonary arterial hypertension (PAH) The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension (PAH).

A nice end to the year for PAH patients in UK. www.gov.uk/government/n...

Rethinking bronchiectasis as an inflammatory disease - The Lancet Respiratory Medicine

The Precision Medicine Era of Bronchiectasis

Rethinking #bronchiectasis refers to a shift in understanding BE as primarily a chronic inflammatory disease rather than just an infective disorder. This emphasizes the need for early identification of at-risk individuals & the development of anti-inflammatory treatments.
tinyurl.com/yfn7e5at

You are far too kind
Great to see you last week 😀

Trial in bronchiectasis has been recently announced ! Watch this space

Heading home after a fantastic #BTSWinter2024 Leaving energised and grateful for friends and the opportunity to talk #mesothelioma in the Plenary Scientific Symposium. Also excited for 2025 under our new BTS President!

Thank you so much to @balrcommunity.bsky.social for the early career researcher award. Very grateful for the opportunity to present at #BTSWinter2024 and thankful to everyone in the Dundee respiratory research group for all your support in this project. @profjdchalmers.bsky.social